Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
- Data on BIBW 2992, an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with EGFR Activating Mutations – (1,2)
-The First Presentation of Data on BIBF 1120 in Ovarian Cancer-
LUX-Lung 2 Interim Results
Interim Phase II data from the LUX-Lung 2 study suggest BIBW 2992 has anti-tumor activity in advanced, second-line, non-small cell lung cancer (NSCLC) patients who have epidermal growth factor receptor (EGFR) mutations.(2)
“Lung cancer kills more people than any other cancer.(3) The LUX-Lung 1 and 2 studies represent an opportunity to investigate BIBW 2992 across a range of different patient populations,” said Dr.
BIBW 2992 is an orally-administered, irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) and human epithelial receptor 2 (HER2) tyrosine kinases.(1) It is the first irreversible EGFR-TKI (tyrosine kinase inhibitor) to reach Phase III for third/fourth-line NSCLC.(4)
In the emerging era of personalized cancer medicine, Boehringer Ingelheim is one of the first companies to prospectively identify appropriate patients for clinical trials based on biomarkers. As part of the LUX-Lung clinical development program, Boehringer Ingelheim is evaluating BIBW 2992 in NSCLC patients who test positive for EGFR activating mutations.(5)
“It is well documented that ‘activating’ mutations that arise in the tyrosine kinase (TK) domain of the EGFR gene are associated with an increased sensitivity to first generation EGFR TKIs.(6,7,8) The majority of patients who initially respond to EGFR TKIs such as gefitinib or erlotinib will eventually develop resistance, often through gaining another mutation, such as the so-called T790M resistance mutation,”(9,10) said Dr. Haehl.
Detailed Findings from LUX-Lung 2:(2)
To date, 409 NSCLC patients have been screened in the LUX-Lung 2 study and 104 patients with EGFR mutations have started treatment with BIBW 2992 once daily. Preliminary data will be presented at ASCO for the first 73 second-line patients, all of whom had previously received one regimen of chemotherapy. Sixty-seven patients are evaluable for response.
Interim data show:(1)
- 64% of patients (43/67) taking BIBW 2992 in the second-line setting experienced a partial response (75% among patients with deletion 19 and 66% in patients with L858R mutations)
- 31% (21/67) of patients taking BIBW 2992 in the second-line setting experienced stable disease
- Median progression-free survival (PFS) in second-line setting is 10.2 months
- The most common related adverse events were diarrhea and skin-related disorders in 86% and 89% of patients respectively [16% and 18% being grade 3 respectively]
- 37 patients had dose reduction and 4 patients discontinued treatment due to adverse events
Findings from LUX-Lung 1
In addition, preliminary data on the demographic and blinded safety data from the ongoing Phase III study, the LUX-Lung 1 trial, will be presented at ASCO for the first time.(5)
The LUX-Lung 1 study addresses a critical need for treatment options for NSCLC patients after failure with a second-line or third-line reversible EGFR inhibitor (i.e., erlotinib or gefitinib). This study recently moved from Phase IIb into Phase III.(5)
“The LUX-Lung 1 study is important as it investigates BIBW 2992 in a group of patients for whom there are no other approved treatment options. These are patients who have already been through standard first-line or second-line chemotherapy and then received treatment with an EGFR TKI. The LUX-Lung 1 study will evaluate whether BIBW 2992 will extend the lives of these cancer patients,”(5) said Dr. Haehl.
First Presentation of Phase II Data on BIBF 1120 in Ovarian Cancer
Data from a Phase II study of BIBF 1120 in patients with ovarian cancer who responded to at least second-line chemotherapy will be presented at ASCO in
“There is a great need for more effective and well tolerated treatment options for women with ovarian cancer.(14) We have a growing body of evidence that anti-angiogenic agents may represent an important treatment approach for this disease,”(15,16,17) commented Prof.
Because angiogenesis plays a pivotal role in the growth of solid tumors,(13) BIBF 1120 is currently being investigated in a number of cancer types including advanced NSCLC. The LUME-Lung Phase III clinical trial program is investigating BIBF 1120 in combination with standard second-line chemotherapy treatments for patients with advanced NSCLC. Approximately 2,600 patients will be enrolled, making this one of the largest Phase III study programs in this NSCLC patient population to date.
About Lung Cancer
Lung cancer is the world’s most common cancer and kills more people than any other cancer.(3,14) In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In
About Ovarian Cancer
According to the 2008 World Health Organization World Cancer Report, as of 2002, ovarian cancer was ranked as the 6th most common cancer in women. Additionally, approximately 204,000 new cases were diagnosed worldwide and 125,000 women died from the disease in 2002.(14) The ACS estimates that about 21,650 new cases of ovarian cancer were diagnosed in
About Boehringer Ingelheim in Oncology
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including various solid tumors and hematological cancers.
The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. BIBW 2992 entered Phase IIb/III clinical development in NSCLC earlier in 2008 and was granted Fast Track designation for a third/fourth line treatment indication in NSCLC by the US Food & Drug Administration. In addition, the LUME-Lung Phase III clinical trial program, which is investigating BIBF 1120 in combination with standard second-line chemotherapy treatments for patients with advanced NSCLC, is ongoing. In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing inhibitors of polo-like kinase 1 (Plk1), a protein that is involved in the processes of cell division. These molecules are in the early stages of clinical development.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim,
In 2008, Boehringer Ingelheim posted net sales of
For more information, please visit http://us.boehringer-ingelheim.com
- Li D et al. “BIBW2992, an irreversible EGFR/HER2 inhibitor highlyeffective in preclinical lung cancer models.” Oncogene 2008;27:4702-4711
- Shih J-Y et al. “A Phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of 1 line of chemotherapy (LUX-Lung 2).” Poster Discussion Presentation.
1 June 2009, Session Time: 8:00AM – 12:00PM. #8013
- “Ask the Expert Online Q&A: Are the number of cancer cases increasing or decreasing in the world?”
1 April 2008. World Health Organization. 5 May 2009. http://www.who.int/features/qa/15/en/print.html.
- Boehringer Ingelheim Pharmaceuticals. “BIBW 2992 and BSC Versus Placebo and BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)”
23 April 2009. ClinicalTrials.gov. 5 May 2009. http://clinicaltrials.gov/ct2/show/NCT00656136?term=BIBW+2992+and+Phase+III&rank=1.
- Yang C-H et al. “Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): a preliminary report. General Poster Session: Lung Cancer – Metastatic.” Saturday
30 May 2009, Session Time: 2:00PM – 6:00PM. # 8062
- Lynch, T. J. et al. “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.” N. Engl. J. Med. 350, 2129-2139 (2004). Available at: http://content.nejm.org/cgi/reprint/350/21/2129.pdf. Accessed on
5 May 2009.
- Paez, J. G. et al. “EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.” Science 304, 1497-1500 (2004). Available at: http://www.sciencemag.org/cgi/reprint/1099314v1.pdf?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=egfr&searchid=1&FIRSTINDEX=0&fdate=//&tdate=//&resourcetype=HWCIT. Accessed on
5 May 2009.
- Pao, W. et al. “EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib.” Proc. Natl Acad. Sci.
USA101, 13306-13311 (2004). Available at: www.pnas.org/cgi/doi/10.1073/pnas.0405220101. Accessed on 5 May 2009.
- Riely G. J. et al. “Clinical Course of Patients with Non -Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib.” Clin. Cancer Res, 12, 839-844(2006). Available at: http://clincancerres.aacrjournals.org/cgi/reprint/12/3/839. Accessed on
5 May 2009.
- Balak, M. N. et al. “Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.” Clin. Cancer Res. 12, 6494-6500 (2006). Available at: http://clincancerres.aacrjournals.org/cgi/reprint/12/21/6494. Accessed on
5 May 2009.
- Ledermann, J. A. “A randomised Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 followign treatment of relapsed ovarian cancer (OC).” Oral presentation, Clinical Science Symposium. Monday,
1 June 2009, Session Time 9:45AM – 11:15AM. # 5501
- Hilberg F. et al. “BIBF1120 a novel, small molecule triple angiokinase inhibitor: profiling as a clinical candidate for cancer therapy.” European Journal of Cancer Supplements. 2004; 2:50.
Lewis J. Kleinsmith. “Understanding Cancer and Related Topics: Understanding Angiogenesis.” Rockville: National Cancer Institute, 2006. Available at: http://cancer.gov/cancertopics/understandingcancer. Accessed on 5 May 2009.
- P Boyle and B Levin (eds). “World Cancer Report 2008.”, World Health Organization: International Agency for Research on Cancer.
Lainie and Russell Schilder. “Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition” J Clin Oncol. 25, 2894-2901 (2007). Available at: http://jco.ascopubs.org/cgi/reprint/25/20/2894. Accessed on 5 May 2009.
- Spannuth, W. A. et al. “Angiogenesis as a Strategic Target for Ovarian Cancer Therapy.” Nature. 5, No.4. (2008). Available at: http://www.nature.com/nrclinonc/journal/v5/n4/pdf/ncponc1051.pdf. Accessed on
5 May 2009.
- Kumaran, G. C. et al. “Minireview: Antiangiogenic Drugs in Ovarian Cancer.” British J of Canc. 100, 1-7 (2009). Available at: http://www.nature.com/bjc/journal/v100/n1/pdf/6604767a.pdf. Accessed on
5 May 2009.
- American Cancer Society. “Cancer Facts and Figures 2008.”
Atlanta: 2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed on 5 May 2009.
- American Cancer Society. “Ovarian Cancer Detailed Guide.”
Atlanta: 2008. Available at: http://documents.cancer.org/114.00/114.00.pdf. Accessed on 5 May 2009.
SOURCE Boehringer Ingelheim